Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cardiometabolic Drugs Market size was valued at USD 56.34 billion in 2024 and is expected to reach USD 123.15 billion by 2037, expanding at around 6.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of cardiometabolic drugs is evaluated at USD 62.07 billion.
The major factor for market growth is the growing chronic diseases among the population owing to the adoption of unhealthy lifestyles, reduced physical activity, and increased consumption of packaged along with junk food. As cardiometabolic drugs are efficient in treating such diseases, their high prevalence is expected to drive market growth. As per the data released by the Centers for Disease Control and Prevention (CDC), six out of ten Americans are diagnosed with at least one chronic disease such as heart disease and stroke, cancer, and diabetes.
The growth of the market can be attributed to factors, such as growing awareness toward the development of novel drugs to minimize the side effects, and escalating demand for drugs to treat cardiometabolic diseases. Some of the cardiometabolic diseases are non-alcoholic liver diseases, heart stroke or attack, insulin resistance, diabetes, and others. In addition, the prevalence of a large pool of a large number of patients owing to the changing lifestyle coupled with the escalation in the usage rate of biomarkers for diagnostic and risk assessment procedures is estimated to propel market growth in the upcoming years. Moreover, the rising focus on developing novel and advanced medicine to treat diseases with reduced side effects is considered to be another factor for the expansion of market size. One of the other factors that are expected to create a positive outlook for revenue generation is the increased fast-paced lifestyles, constant change in eating habits, and escalation in stress levels which is fostering the burden of lifestyles diseases such as diabetes, obesity, hypertension, and others which in turn is generating the need for cardiometabolic drugs during the analysis period.
Cardiometabolic Drugs Sector: Growth Drivers and Challenges
Growth Drivers
-
Growing Cases of Non-Communicable Diseases Across the World – With increasing urbanization, the number of non-communicable diseases across the world is increasing. For fast treatment process for these diseases and to enhance patient experience with reduced pain is expected to increase the demand for cardiometabolic drugs during the forecast period. Recent statistics revealed by the World Health Organization (WHO) stated that non-communicable diseases kill 41 million people each year which is equivalent to 74% of all deaths around the world.
- Escalation in Prevalence of Cardiovascular Diseases – In the recent period, the prevalence of cardiovascular diseases such as coronary heart diseases, strokes, peripheral arterial diseases, and aortic diseases among the global population has surged. As a result, medical professionals have utilized cardiometabolic drugs for faster treatment processes. This trend is anticipated to bring lucrative growth opportunities for market growth in the next few years. As per the latest reports, cardiovascular diseases take almost 17 million lives every year across the globe.
- The Surge in Lifestyle Disorders Including Cancer and Diabetes – For instance, recent statistics revealed that cancer is responsible for approximately 9 million deaths, chronic respiratory diseases for around 4 million deaths, and diabetes for about 2 million deaths every year worldwide.
- Rising Approval of Medicines – The exponential growth in novel drug development and manufacturing process coupled with the rise in approval of medicines is anticipated to ease the commercialization process of cardiometabolic drugs in the next few years. For instance, in 2021, the Center for Drug Evaluation and Research (CDER) approved about 50 novel drugs to be sold out for consumption.
- Upsurge in Research and Development Expenditure – Along with the rapid technological advancement, significant expenditure has been made in research and development activities to develop and manufacture high-quality, effective, and novel cardiometabolic drugs for treatment processes. Hence, creating a positive outlook for market expansion during the forecast period. According to the World Bank, global expenditure on research and development was calculated to be 2.63% of GDP in 2020 up from 2.2% in 2018.
Challenges
-
Rising Risks of Side Effects on the Human Body – Antidiabetics, anticoagulants, hypertension, dyslipidemia drugs, and other cardiometabolic drugs usually have side effects such as dyspepsia, vomiting, nausea, prolonged nosebleeds, passing of blood in urine, and others. Thus, the rising risks of these side effects are projected to slow down the adoption rate of cardiometabolic drugs in the long run which is subsequently expected to hamper the growth of the global cardiometabolic drugs market.
-
Frequent Changes in Guidelines and Security Policies
-
Increased Costs of Medicines
Cardiometabolic Drugs Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.2% |
|
Base Year Market Size (2024) |
USD 56.34 billion |
|
Forecast Year Market Size (2037) |
USD 123.15 billion |
|
Regional Scope |
|
Cardiometabolic Drugs Segmentation
Disease Type (Congestive Heart Failure, Hypertension, Diabetes, Obesity)
The global cardiometabolic drugs market is segmented and analyzed for demand and supply by disease type into congestive heart failure, hypertension, diabetes, obesity, and others. Out of these, the diabetes segment is attributed to holding the largest share of the market during the forecast period. The major factor attributed to segment growth is the rising cases of dibetes among the people and increased diabetic inborn occurrences owing to the rising consumption of junk and adoption of an unhealthy lifestyle. Data released by International Diabetes Federation (IDF) in 2021 showed that about 537 million people aged between 20 to 79 have diabetes which is estimated to reach 783 million over the forecast period. Furthermore, instances of stress and hypertension as a result of engagement in a face-paced lifestyle are also propelling the growth of diabetes among the population which ultimately generates demand for cardiometabolic drugs for the treatment process. Also, as cardiometabolic drugs are highly effective for diabetic patients for diverse app
In the News
Author Credits: Radhika Pawar
- Report ID: 4146
- Published Date: Jan 01, 2025
- Report Format: PDF, PPT
